Noah C. Federman

机构：University of California, Los Angeles, Heidelberg University, University Hospital Heidelberg, Dana-Farber Cancer Institute, Stanford University · ORCID：0000-0002-2627-6772

发表论文 239 篇 · 总被引 9390 次 · h-index 40

代表论文

• The landscape of drug sensitivity and resistance in sarcoma (2024 · Cell stem cell · 被引 66)
• Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma (2024 · Journal of Clinical Oncology · 被引 41)
• Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors (2025 · Journal of Clinical Oncology · 被引 14)
• Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial (2025 · Journal of Clinical Oncology · 被引 12)
• Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance (2025 · Signal Transduction and Targeted Therapy · 被引 8)
• Noninvasive Assessment of Protease Activity in Osteosarcoma via Click Chemistry‐Mediated Enrichment of Extracellular Vesicles (2025 · Advanced Functional Materials · 被引 7)